BTBP(SH:600161) Ge Long Hui A P P·2025-08-05 09:14Core Viewpoint - TianTan Bio (600161.SH) announced that its subsidiary Chengdu Rongsheng Pharmaceutical has completed clinical trials for its product "Recombinant Human Coagulation Factor VIII for Injection" in the population under 12 years old, demonstrating significant efficacy and safety in treating hemophilia A patients [1] Group 1: Clinical Trial Results - The Phase III clinical trial results for the product in the population under 12 years old showed that routine prophylactic treatment significantly reduced the bleeding frequency in children [1] - Improvements were observed in joint health scores (HJHS), number of target joints, and quality of life scores (CHO-KLAT) for patients using the product [1] - The product was also effective in controlling breakthrough bleeding during the prophylactic period [1] Group 2: Safety Analysis - Safety analysis results indicated that the drug has good safety profiles for hemophilia A patients in the clinical application process [1]